Skip to content

Transcriptional Analysis of Mechanisms in Liver Failure and Sepsis

Transcriptional Analysis of Mechanisms and Predictors in Acute Liver Failure and Sepsis

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07131969
Acronym
MAP-ALF
Enrollment
100
Registered
2025-08-20
Start date
2025-09-30
Completion date
2028-09-30
Last updated
2025-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Liver Failure, Sepsis

Keywords

acute liver failure, sepsis, transcriptional analysis, predictors, paracetamol overdose, acetaminophen overdose

Brief summary

Context Acute liver failure (ALF) is a life-threatening condition that occurs on the background of a healthy liver. The most common cause of acute liver failure in the UK is paracetamol overdose. Acute liver failure results from liver damage and activation of the body's inflammatory defences with subsequent damage to other organs including kidneys, lungs and heart. This often requires life support in an intensive care unit before liver transplantation (LT), the only currently available and effective rescue treatment for acute liver failure. Challenge Patient factors and organ availability limit who can benefit from liver transplant. At present there are no effective alternative therapies for patients who do not get a liver transplant, and survival rates in these situations are poor. The underlying mechanisms of inflammation are poorly understood, thus therapies are limited. Aim The investigators research aims to understand the mechanisms that underpin the inflammation seen in acute liver failure by studying the inflammatory cells in the blood and examining their cellular programmes. This will allow the investigators to identify pathways that are activated and understand how the liver and blood interact to spread inflammation around the body. The investigators aim to identify targets for disease-modifying therapies to avert the need for liver transplant. Importance Understanding how the body responds to acute liver failure, and whether there are different patterns of inflammatory response, will enable trials of immune-modulating drugs to prevent the need for liver transplantation or prolong the time a patient can wait for an organ. This has the potential to help improve organ availability for other patients and save lives in acute liver failure.

Interventions

OTHERblood draw

Venous blood sampling into Tempus tube for RNA-sequencing

Sponsors

European Society of Intensive Care Medicine
CollaboratorOTHER
University of Cambridge
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* acute liver failure due to acetaminophen (paracetamol) overdose admitted to ICU * all cause sepsis admitted to ICU

Exclusion criteria

* age \<16y

Design outcomes

Primary

MeasureTime frame
MortalityFrom enrolment until at least 1-year

Secondary

MeasureTime frameDescription
Transplant free survivalFrom enrolment to at least one year30-day and 1-year survival without transplant
Length of stay - ICU and hospitalFrom enrolmentNumber of days stayed in ICU and in-hospital
Transplant free mortalityFrom enrolment until death (at least until 1year)Death without transplant

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026